COVID-19 associated mucormycosis – An emerging threat

Chien Ming Chao, Chih Cheng Lai, Wen Liang Yu

研究成果: 雜誌貢獻回顧型文獻同行評審

18 引文 斯高帕斯(Scopus)


Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly become a global threaten since its emergence in the end of 2019. Moreover, SARS-CoV-2 infection could also present with co-infection or secondary infection by other virus, bacteria, or fungi. Among them, mucormycosis is a rare but aggressive fungal disease and it mainly affects patients particularly with poorly controlled diabetes mellitus with diabetic ketoacidosis (DKA). We here did a comprehensive review of literature reporting COVID-19 associated with mucormycosis (CAM) cases, which have been reported worldwide. The prevalence is higher in India, Iran, and Egypt than other countries, particularly highest in the states of Gujarat and Maharashtra in India. Poor diabetic control and the administration of systemic corticosteroids are the common precipitating factors causing mucormycosis in the severe and critical COVID-19 patients. In addition, COVID-19 itself may affect the immune system resulting in vulnerability of the patients to mucormycosis. Appropriate treatments of CAM include strict glycemic control, extensive surgical debridement, and antifungal therapy with amphotericin B formulations.
頁(從 - 到)183-190
期刊Journal of Microbiology, Immunology and Infection
出版狀態已發佈 - 4月 2022

ASJC Scopus subject areas

  • 免疫學和過敏
  • 免疫學與微生物學 (全部)
  • 微生物學(醫學)
  • 傳染性疾病


深入研究「COVID-19 associated mucormycosis – An emerging threat」主題。共同形成了獨特的指紋。